Categories

A sample text widget

Etiam pulvinar consectetur dolor sed malesuada. Ut convallis euismod dolor nec pretium. Nunc ut tristique massa.

Nam sodales mi vitae dolor ullamcorper et vulputate enim accumsan. Morbi orci magna, tincidunt vitae molestie nec, molestie at mi. Nulla nulla lorem, suscipit in posuere in, interdum non magna.

Ferinject Treatment is Available Soon in MENA Pharmaceutical Market

ViforA licensing and distribution agreement in was launched between Pharmaceuticals Ltd. and Vifor Pharma, a wholly-owned subsidiary of the Galenica Group. According to this agreement Hikma will market , Vifor Pharma‘s innovative treatment for , in the Middle East and North African region (““). Algeria, Egypt, Iraq, Jordan, Lebanon, Libya, Morocco, South Sudan, Sudan, Syria, Tunisia and Yemen are included in the agreement. Access to Ferinject®, an efficacious, well tolerated and convenient treatment for iron deficiency will be easier for patients in these countries.

Hikma will receive exclusive rights to market and distribute a product that complements its portfolio of prescription pharmaceuticals. Dr. David Ebsworth, CEO of Vifor Pharma said “This collaboration is great news for Vifor Pharma. It is also very good news for all patients suffering from iron deficiency in the MENA region. These patients will soon have access to a new and much-needed therapeutic option. I am delighted that Hikma – a company with great expertise and standing – shares our view of the potential of Ferinject® and has decided to contribute to the further success of the product”.

Ferinject® has been demonstrated to have a powerful impact in the treatment of iron deficiency. This agreement enables us to bring another world class product to patients in the MENA region and we look forward to a long and successful collaboration with Vifor Pharma” commented Said Darwazah, CEO of Hikma Pharmaceuticals. In the next five years, MENA pharmaceutical market is expected to expand with annually rate about 11%. This expansion will provide excellent growth potential for high quality innovative pharmaceuticals such as Ferinject®. Lebanon included in the MENA region has now the permission to market the product. The other countries will follow Lebanon soon while both companies are hopeful as Ferinject® will be registered and made available to patients within a very short time.

VN:F [1.9.22_1171]
Rating: 0.0/10 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>